Revance Reports Fourth Quarter and Full Year 2021 Financial Results, Provides Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/28/2026

1. ON
2. SYNA
3. SPY
4. MU
5. VEON
6. AAPL
7. DRI
8. FDXF
9. RKLB
10. SPCX

Go back to Revance Reports Fourth Quarter and Full Year 2021 Financial Results, Provides Corporate Update

Revance Therapeutics (RVNC) Tops Q4 EPS by 9c

February 28, 2022 4:36 PM EST

Revance Therapeutics (NASDAQ: RVNC) reported Q4 EPS of ($0.93), $0.09 better than the analyst estimate of ($1.02). Revenue for the quarter came in at $26 million versus the consensus estimate of $24.27 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

... More